证券代码：301075 证券简称：多瑞医药 公告编号：2026-001 西藏多瑞医药股份有限公司 关于注销募集资金专项账户的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 心建设项目"，将募投项目"学术推广及营销网络扩建项目"结项，并 将剩余资金用于偿还银行贷款和永久补充流动资金。具体内容详见公 司于 2025 年 10 月 24 日在巨潮资讯网（www.cninfo.com.cn）披露的 相关公告。 鉴于公司的募集资金已按上述要求使用完毕，为降低公司管理成 本、规范银行账户使用，公司对上述募集资金专户办理了注销手续。 截至本公告披露日，公司已办理完成上述募集资金专户的注销手 续，并及时通知了保荐机构和保荐代表人。上述募集资金专户注销后， 相应的募集资金监管协议随之终止。 二、募集资金存放和管理情况 为了规范募集资金的管理和使用，保护投资者的利益，根据《上 市公司募集资金监管规则》、《深圳证券交易所创业板股票上市规则》、 《深圳证券交易所创业板上市公司规范运作指引》等法律、法规和规 范性文件要求，以及公司《募集资金管理制度》的规定， ...

Group 1 - The core viewpoint of the news is that Duorui Pharmaceutical has shown significant trading activity, with a notable increase in financing buy-ins and a high financing balance relative to its market value [1] - On December 24, Duorui Pharmaceutical's stock rose by 2.09%, with a trading volume of 59.29 million yuan and a net financing buy of 4.89 million yuan [1] - The company's financing balance reached 214 million yuan, accounting for 5.09% of its circulating market value, indicating a high level of financing activity compared to the past year [1] Group 2 - As of September 30, the number of shareholders for Duorui Pharmaceutical was 6,361, a decrease of 16.60% from the previous period, while the average circulating shares per person increased by 19.90% to 12,576 shares [2] - For the period from January to September 2025, Duorui Pharmaceutical reported a revenue of 137 million yuan, a year-on-year decrease of 31.68%, and a net profit attributable to shareholders of -79.73 million yuan, representing a significant decline of 366.82% [2] - Since its A-share listing, Duorui Pharmaceutical has distributed a total of 59.87 million yuan in dividends, with 9.87 million yuan distributed over the past three years [2]

Group 1 - The core viewpoint of the news is that Duorui Pharmaceutical's stock performance and financial metrics indicate a challenging period, with significant declines in revenue and net profit, alongside high financing levels [1][2]. Group 2 - On December 23, Duorui Pharmaceutical's stock rose by 3.14%, with a trading volume of 72.61 million yuan. The financing buy-in amount was 3.21 million yuan, while the financing repayment was 7.48 million yuan, resulting in a net financing buy of -4.28 million yuan [1]. - As of December 23, the total financing and securities lending balance for Duorui Pharmaceutical was 209 million yuan, accounting for 5.08% of its market capitalization, which is above the 90th percentile level over the past year [1]. - The company has not engaged in securities lending activities on December 23, with no shares sold or repaid, indicating a high level of inactivity in this area [1]. - Duorui Pharmaceutical, established on December 22, 2016, and listed on September 29, 2021, focuses on the research, production, and sales of chemical drug formulations and their raw materials. The revenue composition is as follows: formulations 37.60%, intermediates 35.78%, raw materials 21.64%, and others 4.98% [1]. - As of September 30, the number of shareholders for Duorui Pharmaceutical was 6,361, a decrease of 16.60% from the previous period, while the average circulating shares per person increased by 19.90% to 12,576 shares [2]. - For the period from January to September 2025, Duorui Pharmaceutical reported a revenue of 137 million yuan, a year-on-year decrease of 31.68%, and a net profit attributable to shareholders of -79.73 million yuan, representing a year-on-year decline of 366.82% [2]. - Since its A-share listing, Duorui Pharmaceutical has distributed a total of 59.87 million yuan in dividends, with 9.87 million yuan distributed over the past three years [2].

Core Viewpoint - The company, Duori Pharmaceutical (301075.SZ), has announced a plan to repurchase shares through a concentrated bidding method, which will be followed by a reduction in shareholding [1] Group 1: Share Repurchase Plan - The board of directors has approved a proposal regarding the share repurchase and subsequent reduction plan [1] - The company intends to sell back the repurchased shares within a period of six months, starting from 15 trading days after the announcement [1] - The maximum number of shares to be sold is 1.0445 million, which represents 1.31% of the company's total share capital [1] Group 2: Sale Conditions - The sale price of the repurchased shares will be determined based on the secondary market price [1] - The implementation period for the sale is set from January 14, 2026, to July 13, 2026, excluding any periods prohibited by the China Securities Regulatory Commission and the Shenzhen Stock Exchange [1]

Core Viewpoint - Duori Pharmaceutical (301075.SZ) announced the plan to sell repurchased shares through a centralized bidding method, with a total of up to 1,044,500 shares, representing 1.31% of the company's total share capital [1] Group 1 - The sale period for the repurchased shares will be from January 14, 2026, to July 13, 2026, excluding the periods prohibited by the China Securities Regulatory Commission and the Shenzhen Stock Exchange [1] - The selling price of the repurchased shares will be determined based on the secondary market price [1]

Group 1 - The core viewpoint of the article is that Duorui Pharmaceutical (301075.SZ) has decided to terminate several fundraising projects and return the remaining funds to repay bank loans and supplement working capital permanently [1] - The company has approved the termination of the following projects: "Annual production of 16 million bags of sodium acetate injection (Phase III project)", "New product development project", and "Tibet headquarters and R&D center construction project" [1] - The project "Academic promotion and marketing network expansion project" has been concluded [1] Group 2 - To implement the termination of the aforementioned fundraising projects, Hubei Duorui plans to reduce its registered capital by 241.9 million yuan [1] - After the capital reduction, Hubei Duorui's registered capital will change from 271.9 million yuan to 30 million yuan [1]

多瑞医药(301075.SZ)公告，公司董事会审议通过了《关于回购股份集中竞价减持计划的议案》，根据 公司于2024年2月8日披露的《回购报告书》之用途约定，同意公司以集中竞价方式出售已回购股份,实 施期限为自本公告披露之日起15个交易日后的6个月内(即2026年1月14日至2026年7月13日，根据中国证 监会及深圳证券交易所相关规定禁止出售的期间除外)，本次拟出售回购股份不超过104.45万股，占公 司总股本的1.31%，出售价格根据二级市场价格确定。 ...

Core Viewpoint - The company, Duori Pharmaceutical (301075.SZ), has approved a share repurchase plan to sell back shares through centralized bidding, with a total of up to 1.0445 million shares, representing 1.31% of the company's total share capital [1] Group 1 - The board of directors has passed a resolution regarding the share repurchase plan [1] - The repurchased shares will be sold within a period starting 15 trading days after the announcement and lasting for 6 months, specifically from January 14, 2026, to July 13, 2026 [1] - The selling price of the repurchased shares will be determined based on the secondary market price [1]

Group 1 - The core point of the article is that Duori Pharmaceutical announced a share repurchase plan, allowing the company to sell back its repurchased shares within a specified timeframe [1] - The company plans to sell up to approximately 1.04 million shares, which represents 1.31% of its total share capital, with the sale price determined by the secondary market [1] - The board meeting to approve this plan is scheduled for December 19, 2025, and the sale period will be from January 14, 2026, to July 13, 2026 [1] Group 2 - For the year 2024, Duori Pharmaceutical's revenue composition is 57.85% from the pharmaceutical manufacturing sector and 42.15% from other sources [1] - As of the latest report, the market capitalization of Duori Pharmaceutical is 4.1 billion yuan [2]

西藏多瑞医药股份有限公司 董事及高级管理人员持有本公司股份 第一条 为加强西藏多瑞医药股份有限公司（以下简称"公司"或"本公司"）对董 事和高级管理人员买卖本公司股票及衍生品种的管理，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、、《深圳证券交易所创业板股票上市规则》（以下简称"《上市规则》"）、 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》（以 下简称"《规范运作指引》"）、《深圳证券交易所上市公司自律监管指引第18号—— 股东及董事、高级管理人员减持股份》、《深圳证券交易所上市公司自律监管指引第 10号——股份变动管理》（以下简称"《监管指引》"）等相关法律、法规、规范性文 件以及《西藏多瑞医药股份有限公司章程》（以下简称"《公司章程》"）的规定，结 合公司客观实际情况，制定本制度。 第二条 公司董事、高级管理人员和证券事务代表在买卖本公司股票及其衍生品 种前，应知悉并遵守《公司法》《证券法》等法律、行政法规、部门规章、规范性文 件、《上市规则》《规范运作指引》和深圳证券交易所（以下简称"深交所"）其他相 关规定中 ...